Post by Dicot Pharma AB

We are pleased to publish Dicot Pharma's 2025 Annual Report, highlighting a successful year and continued progress in the development of the drug candidate LIB-01 for erectile dysfunction. Positive outcomes from the phase 2a trial and a better understanding of LIB-01’s mechanism of action have established a strong basis for further development and attracted greater international interest.   Read the full report: 👉 In Swedish - https://lnkd.in/gWkqjbtz 👉 In English - https://lnkd.in/gy9ViHG3 #annualreport #erectiledysfunction #drugdevelopment #innovation